Pharmaceutical use of FAM19A5 involved in regulating gliogenesis
US10640557B2 · kind B2 · utility
6Cited by
1References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 11, 2017 |
| Grant date | May 5, 2020 |
| Priority date | — |
| Expiry date | Apr 5, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/47
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.